- Roquette to acquire IFF Pharma Solutions, a producer of excipients for oral dosage solutions.
- IFF Pharma Solutions has revenues of approximately $1B and around 1,100 employees.
- The acquisition is expected to close in the first half of 2025, pending regulatory approval.
- IFF Pharma Solutions operates 10 R&D and production sites globally.
Acquisition Overview
Roquette, a leader in plant-based ingredients and pharmaceutical excipients, has announced an agreement to acquire IFF Pharma Solutions. This acquisition aims to strengthen Roquette's position in the pharmaceutical industry by expanding its product range and accelerating growth.
Company Profiles
IFF Pharma Solutions, headquartered in New York, is a global producer of excipients for oral dosage solutions. The company generates approximately $1B in revenue, operates 10 research and development and production sites worldwide, and employs around 1,100 people. Its client base includes major pharmaceutical, food, and nutraceutical companies.
Strategic Impact
This acquisition is a significant strategic move for Roquette, enhancing its presence in the excipients market, which has strong growth prospects. It will also expand Roquette's footprint in the US and boost its formulation capabilities and drug delivery research and development.
Timeline and Conditions
The transaction is expected to close in the first half of 2025, subject to regulatory clearance and other customary closing conditions.
